Paragraph 2

Changes not yet applied. Later legislation changes this provision in ways not yet written into the text below:

Sch.4, para.4A added by Medicines (Products for Human Use—Fees) 2000 reg.6
Sch 4, para 4A am by Medicines for Human Use and Medical Devices (Fees and Miscellaneous Amendments) 2001 reg 5(11)
Sch. 4 para. 5 words inserted by Medicines for Human Use (Clinical Trials Fees Amendments) 2004 reg. 12(a)
Sch. 4 para. 6 words inserted by Medicines for Human Use (Clinical Trials Fees Amendments) 2004 reg. 12(b)
Sch 4, para 2 am by Medicines for Human Use (Fees Amendments) 2005 reg 18(1), (2)
Sch 4, para 4B added by Medicines for Human Use (Fees Amendments) 2005 reg 18(1), (3)
Sch 4, para 6 am by Medicines for Human Use (Fees Amendments) 2005 reg 18(1), (4)
Sch. 4 para. 4A(a)(i) words substituted by Medicines (Codification Amendments Etc.) 2002 reg. 16(k)
Sch. 4 para. 4A(b)(i) words substituted by Medicines (Codification Amendments Etc.) 2002 reg. 16(k)

In connection with a major application for a marketing authorization for which the fee payable is that specified in entry 1(c) of the Table in paragraph 1 of Part II of Schedule 1, the fee payable under regulation 4(a) shall, if the applicant so requests in writing, be payable as to 25% at the time of the application and as to 75% within 30 days following written notice from the licensing authority that the application has been determined.